|
US9829494B2
(en)
|
2005-12-01 |
2017-11-28 |
Adrenomed Ag |
Methods of treatment using ADM antibodies
|
|
RU2494108C2
(ru)
|
2006-04-07 |
2013-09-27 |
Аерпио Терапетикс, Инк. |
Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
|
|
AU2014243418B2
(en)
*
|
2010-04-30 |
2016-09-22 |
Molecular Partners Ag |
Modified binding proteins inhibiting the VEGF-A receptor interaction
|
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
|
PL2643349T3
(pl)
*
|
2010-11-26 |
2020-03-31 |
Molecular Partners Ag |
Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
|
|
EA201391607A1
(ru)
|
2011-04-29 |
2014-04-30 |
Янссен Байотек, Инк. |
Связывающие il4/il13 белки с повторами и их применение
|
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
|
WO2013056240A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome and cancer
|
|
IL283215B2
(en)
|
2011-11-16 |
2024-05-01 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same
|
|
ES2494190T3
(es)
|
2011-11-16 |
2014-09-15 |
Adrenomed Ag |
Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
|
|
HRP20170427T1
(hr)
|
2011-11-16 |
2017-06-16 |
Sphingotec Gmbh |
Testovi na adrenomedulin i postupci određivanja zrelog adrenomedulina
|
|
EP2780370B1
(en)
|
2011-11-16 |
2019-09-25 |
AdrenoMed AG |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
|
|
LT3553084T
(lt)
|
2011-11-16 |
2023-03-10 |
Adrenomed Ag |
Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme
|
|
PT2780371T
(pt)
|
2011-11-16 |
2019-01-30 |
Adrenomed Ag |
Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
|
|
CN103308673B
(zh)
|
2012-03-08 |
2017-05-31 |
思芬构技术有限公司 |
用于预测雌性对象中发生心血管事件的风险的方法
|
|
CN103308670B
(zh)
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
|
CN103308689B
(zh)
|
2012-03-08 |
2017-04-12 |
思芬构技术有限公司 |
用于预测雌性对象中患上癌症的风险或诊断癌症的方法
|
|
ES2753135T3
(es)
*
|
2012-05-07 |
2020-04-07 |
Allergan Inc |
Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
|
|
PL3777834T3
(pl)
|
2012-06-01 |
2022-05-30 |
Novartis Ag |
Strzykawka
|
|
WO2014001442A1
(en)
*
|
2012-06-28 |
2014-01-03 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to platelet-derived growth factor
|
|
AU2012101677B4
(en)
|
2012-07-03 |
2012-12-20 |
Novartis Ag |
Device
|
|
AU2013100070B4
(en)
*
|
2012-07-03 |
2013-04-04 |
Novartis Ag |
Use of device
|
|
DE202013000688U1
(de)
|
2012-07-03 |
2013-03-05 |
Novartis Ag |
Glas-Spritze
|
|
EP2890389A1
(en)
*
|
2012-08-28 |
2015-07-08 |
Novartis AG |
Use of a vegf antagonist in treating ocular vascular proliferative diseases
|
|
US9664695B2
(en)
|
2012-10-02 |
2017-05-30 |
Sphingotec Gmbh |
Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
ES2879023T3
(es)
|
2013-01-08 |
2021-11-19 |
Sphingotec Gmbh |
Niveles en ayunas de la hormona de crecimiento como marcador predictivo de riesgo cardiovascular
|
|
EP2961773B1
(en)
*
|
2013-02-26 |
2019-03-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
JP6649246B2
(ja)
*
|
2013-03-14 |
2020-02-19 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法
|
|
SG11201507774YA
(en)
|
2013-03-20 |
2015-10-29 |
Sphingotec Gmbh |
Adrenomedullin to guide therapy of blood pressure decline
|
|
FR3004650B1
(fr)
*
|
2013-04-22 |
2015-05-29 |
Affilogic |
Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
|
|
CN105209483B
(zh)
|
2013-05-31 |
2021-07-27 |
分子组合公司 |
与肝细胞生长因子结合的设计锚蛋白重复蛋白
|
|
EP3010526A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating macular edema
|
|
US20160137717A1
(en)
|
2013-06-20 |
2016-05-19 |
Gabriela Burian |
Use of a vegf antagonist in treating choroidal neovascularisation
|
|
WO2014203181A1
(en)
|
2013-06-20 |
2014-12-24 |
Novartis Ag |
Treatment of polypoidal choroidal vasculopathy
|
|
EP3019526A1
(en)
|
2013-07-11 |
2016-05-18 |
Novartis AG |
Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
RU2676303C2
(ru)
|
2013-07-11 |
2018-12-27 |
Новартис Аг |
Использование антагониста vegf для лечения ретролентальной фиброплазии
|
|
DK4374873T3
(da)
|
2013-07-12 |
2025-11-03 |
Astellas Us Llc |
Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
|
|
PT3065761T
(pt)
*
|
2013-11-05 |
2020-02-21 |
Allergan Inc |
Método de tratamento de condições oculares com um darpin anti-vegf
|
|
CN106456757A
(zh)
|
2014-05-12 |
2017-02-22 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
EP3002589A1
(en)
|
2014-10-01 |
2016-04-06 |
sphingotec GmbH |
A method for stratifying a female subject for hormone replacement therapy
|
|
KR102427117B1
(ko)
*
|
2015-04-02 |
2022-07-29 |
몰리큘라 파트너스 아게 |
혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
|
|
CN107667294B
(zh)
|
2015-04-24 |
2021-12-17 |
思芬构技术有限公司 |
用于预测慢性肾病发生风险的方法
|
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
|
CA3005132A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Coated syringe for ophthalmic formulations containing a vegf antagonist
|
|
EP3377100B1
(en)
|
2015-11-18 |
2025-02-26 |
Formycon AG |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
|
CN108290004A
(zh)
|
2015-11-18 |
2018-07-17 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
WO2018218013A2
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
US10576128B2
(en)
|
2016-01-26 |
2020-03-03 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
CN115951066A
(zh)
|
2016-02-29 |
2023-04-11 |
麦恩泰科特有限公司 |
可用于治疗湿性年龄相关性黄斑变性的预测性标志物
|
|
DE112017002105T5
(de)
|
2016-04-21 |
2019-04-25 |
Sphingotec Therapeutics Gmbh |
Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren
|
|
EP3474887A1
(en)
|
2016-06-27 |
2019-05-01 |
AiCuris Anti-infective Cures GmbH |
Hcmv entry inhibitors
|
|
RU2019103403A
(ru)
|
2016-07-08 |
2020-08-10 |
Сфинготек Гмбх |
Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
|
|
BR112019001206A2
(pt)
|
2016-07-20 |
2019-06-25 |
Aerpio Therapeutics Inc |
anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
|
|
CN109790206A
(zh)
|
2016-09-22 |
2019-05-21 |
分子组合公司 |
重组结合蛋白及其用途
|
|
EP3309550A1
(en)
|
2016-10-12 |
2018-04-18 |
sphingotec GmbH |
Method for the detection of apolipoprotein e4
|
|
EP3339324A1
(en)
|
2016-12-22 |
2018-06-27 |
sphingotec GmbH |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
|
JP7727371B2
(ja)
|
2016-12-16 |
2025-08-21 |
アドレノメト アクチェンゲゼルシャフト |
うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン(ADM)抗体、または抗ADM抗体フラグメント、または抗ADM非Ig足場
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
EP3630043A1
(en)
|
2017-05-24 |
2020-04-08 |
Formycon AG |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
EP3631459A1
(en)
|
2017-05-30 |
2020-04-08 |
SphingoTec GmbH |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
KR20200038303A
(ko)
*
|
2017-08-18 |
2020-04-10 |
캠브리지 엔터프라이즈 리미티드 |
모듈형 결합 단백질
|
|
HRP20241795T1
(hr)
|
2017-09-25 |
2025-03-14 |
Adrenomed Ag |
Anti-adrenomedulin (adm) – vezujući entitet za uporabu u terapiji ili prevenciji simptoma bolesti
|
|
WO2019077082A1
(en)
|
2017-10-18 |
2019-04-25 |
Adrenomed Ag |
SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM)
|
|
JP7411546B2
(ja)
|
2017-10-24 |
2024-01-11 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
初回心血管イベントの予測のためのセレノプロテインp
|
|
KR102835427B1
(ko)
|
2017-10-25 |
2025-07-21 |
4틴4 파마슈티컬스 게엠베하 |
특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도
|
|
CN119770645A
(zh)
|
2018-02-08 |
2025-04-08 |
斯弗因高泰克有限公司 |
用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用
|
|
EP3569614A1
(en)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
|
|
EP3586865A1
(en)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
|
|
WO2020068653A1
(en)
|
2018-09-24 |
2020-04-02 |
Aerpio Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
|
|
BR112021010069A2
(pt)
|
2018-12-20 |
2021-11-23 |
Sphingotec Gmbh |
Selenoproteína p em insuficiência cardíaca
|
|
CN113557031A
(zh)
|
2018-12-21 |
2021-10-26 |
4Teen4制药有限公司 |
使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
|
|
WO2020245746A1
(en)
|
2019-06-04 |
2020-12-10 |
Molecular Partners Ag |
Multispecific proteins
|
|
AU2020328194A1
(en)
|
2019-08-15 |
2022-03-17 |
Sphingotec Gmbh |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
|
|
JP2022546061A
(ja)
|
2019-08-30 |
2022-11-02 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ショック症治療のための治療法の誘導および/または治療法の監視
|
|
IL293698A
(en)
|
2019-12-11 |
2022-08-01 |
Molecular Partners Ag |
Recombinant peptide-mhc complex binding proteins, their production and use
|
|
EP3871689A1
(en)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
|
|
CN115244080A
(zh)
|
2020-02-27 |
2022-10-25 |
艾德里诺医药公司 |
用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
|
|
US20230193348A1
(en)
|
2020-02-27 |
2023-06-22 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
|
|
US20230250166A1
(en)
|
2020-02-27 |
2023-08-10 |
Adrenomed Ag |
Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
|
|
EP3922993A1
(en)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
AU2021238591A1
(en)
|
2020-03-16 |
2022-11-17 |
Adrenomed Ag |
Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin
|
|
BR112022017277A2
(pt)
|
2020-03-16 |
2022-10-18 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 em pacientes infectados com coronavírus
|
|
JP2023525518A
(ja)
|
2020-05-06 |
2023-06-16 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
新規アンキリンリピート結合タンパク質とその用途
|
|
US20240279290A1
(en)
|
2020-05-14 |
2024-08-22 |
Molecular Partners Ag |
Multispecific proteins
|
|
EP4023218A1
(en)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Combination therapy for patients having acute and/or persistent dyspnea
|
|
AU2021403833A1
(en)
|
2020-12-16 |
2023-07-27 |
Molecular Partners Ag |
Novel slow-release prodrugs
|
|
CA3211368A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
|
US20240317852A1
(en)
|
2021-03-09 |
2024-09-26 |
Molecular Partners Ag |
Novel darpin based cd33 engagers
|
|
BR112023018293A2
(pt)
|
2021-03-09 |
2023-10-31 |
Molecular Partners Ag |
Acopladores de célula t multiespecíficos à base de darpin
|
|
EP4305063A1
(en)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Protease cleavable prodrugs
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
CN117529664A
(zh)
|
2021-06-18 |
2024-02-06 |
思芬构技术有限公司 |
用于预测脓毒症和脓毒性休克的方法
|
|
US20240310387A1
(en)
|
2021-06-29 |
2024-09-19 |
Berysol Gmbh |
Composite biomarker for the identification of selenium deficiency in a bodily fluid
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
WO2023110983A1
(en)
|
2021-12-14 |
2023-06-22 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity and their use
|
|
CA3254142A1
(en)
|
2022-03-15 |
2023-09-21 |
Adrenomed Ag |
STABLE AQUEOUS FORMULATION OF AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM ANTIBODY FRAGMENT
|
|
AU2023315168A1
(en)
|
2022-07-29 |
2025-02-13 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
|
AU2023313376A1
(en)
|
2022-07-29 |
2025-03-06 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
|
WO2024028278A1
(en)
|
2022-08-01 |
2024-02-08 |
Molecular Partners Ag |
Charge modified designed repeat domains and their use
|
|
WO2024038307A1
(en)
|
2022-08-19 |
2024-02-22 |
Novartis Ag |
Dosing regimens for sars-cov-2 binding molecules
|
|
WO2024059686A2
(en)
*
|
2022-09-15 |
2024-03-21 |
The Regents Of The University Of California |
Darpin backbones and rigidified electron microscopy imaging scaffolds
|
|
JP2025541138A
(ja)
|
2022-12-15 |
2025-12-18 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
重篤な患者における肺機能の改善のためのdpp3阻害剤
|
|
EP4673159A1
(en)
|
2023-02-27 |
2026-01-07 |
Molecular Partners AG |
Darpins for use in reducing renal accumulation of drugs
|
|
JP2026510789A
(ja)
|
2023-03-17 |
2026-04-10 |
ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ペプチジルグリシンα-アミド化モノオキシゲナーゼ(PAM)の測定法及び診断目的のためのその使用
|
|
EP4687942A1
(en)
|
2023-03-29 |
2026-02-11 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
|
|
CN121889677A
(zh)
|
2023-09-25 |
2026-04-17 |
思芬构技术有限公司 |
用于肾移植患者中移植物功能降低的早期诊断、早期预测、监测或严重程度预测的方法
|
|
WO2025146491A1
(en)
|
2024-01-05 |
2025-07-10 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
|
|
WO2025229075A1
(en)
|
2024-05-03 |
2025-11-06 |
Sphingotec Gmbh |
A method for the specific determination of proenkephalin fragment 119-159
|
|
WO2025248139A1
(en)
|
2024-05-31 |
2025-12-04 |
4TEEN4 Pharmaceuticals GmbH |
Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
|
|
EP4675277A1
(en)
|
2024-07-05 |
2026-01-07 |
Predemtec AG |
A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease
|
|
WO2026046968A1
(en)
|
2024-08-26 |
2026-03-05 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 binders for the treatment of endothelial dysfunction
|
|
WO2026046978A1
(en)
|
2024-08-26 |
2026-03-05 |
Pam Theragnostics Gmbh |
Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects
|